Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Links shared publicly online about this topic.

  • 0
    total visits

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

news-medical.net —

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.

View full resource at news-medical.net

Tags: Cancer, Multiple Myeloma, Prostate Cancer, Prostate, Men's Health

  • Share

Most Recently Shared on December 14, 2011 at 4:04 pm By:

prostatecancers News-Medical.Net

Prostate Cancer: Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM: C... http://t.co/m4attbxF

4 months ago...

Reply

Retweet

Favorite

Also Shared By:

News-Medical.Net News-Medical.Net

Advertisement